



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: **17-06-2008**

Mr. Yasin Tahir,
Director General, IPO-Pakistan
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR
THE WEEKENDING 31-5-2008 TO BE PUBLISHED 18-06-
2008 IN THE GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

**GOVERNMENT OF PAKISTAN
THE PATENT OFFICE**

2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: **17-06-2008**

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR
THE WEEKENDING 31-5-2008 TO BE PUBLISHED 18-06-
2008 IN THE GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

581/2008	<u>26-5-2008</u> Bayer HealthCare LLC., USA (Priority 10-12-07 USA)	“Rapid charging and power management of a battery-powered fluid analyte meter”
582/2008	Bayer HealthCare LLC. USA (Priority 10-12-07 USA)	“Interface for a health measurement and monitoring system”
583/2008	<u>27-5-2008</u> Syngenta Limited, United Kingdom (priority 29-5-07 UK)	“Novel herbicides”
584/2008	Nestec S.A., Switzerland (Priority 04-6-07 Europe)	“Baked composition”
585/2008	S. Alim Uddin Warsi Karachi, Pakistan	“A process for the production of dietary supplement for reducing body fat-dietavit”
586/2008	Sumitomo Chemical Company, Limited Japan (Priority 30-5-07 Japan)	“Thioimidate compound and use thereof for controlling pests”
587/2008	1. Ehime university 2. Otsuka Pharmaceutical Co. Ltd. Japan (Priority 28-5-07 Japan)	“Primers for detecting plasmodium”
588/2008	Toyota Jidosha Kabushiki Kaisha Japan (Priority 30-5-07 Japan)	“Knocking determination device and knocking determination method for internal combustion engine”
589/2008	Honda Motor Co., Ltd Japan (Priority 30-5-07 Japan)	“Leg shield structure of motorcycle”
590/2008	<u>28-5-2008</u> Zakiuddin Ahmed Karachi, Pakistan	“A Process for the production of alternate fuel oil (named as FR-AFO-

		I) from Pakistani coal”
591/2008	Schering-Plough Ltd., Switzerland (Priority 30-5-07 USA)	A process for preparing oxazoline-protected aminodiol compounds, useful as intermediates to florfenicol”
592/2008	Schering Corporation USA (Priority -1-6-07 USA)	“Gamma Secretase modulators”
593/2008	Schering Corporation USA (Priority -1-6-07 USA)	“Gamma Secretase modulators”
594/2008	1. Bouleckos Stamatis and 2. Panagopoulos Dimitrios, Greek	“Amplifier of acceleration signal- auto pilot, for new technology cars”
595/2008	1. Council of Scientific and Industrial Research, India (Priority 01-6-07 India)	“A novel method for simultaneous detection and discrimination of bacterial, fungal, parasitic and viral infections of eye and central nervous system”
596/2008	Syngenta Participation AG, Switzerland Divisional	“Process for the hydrogenation of imines”
597/2008	E. I. DU Pont DE Nemours and Company, USA (Priority 31-5-07 USA)	“3-cyano-4-triazolyl phenylisoxazoline invertebrate pest control agents”
	<u>29-5-2008</u>	
598/2008	SGX Pharmaceuticals, Inc. USA (Priority 29-5-07 USA)	“Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators”
599/2008	Honda Motor Co., Ltd. Japan (Priority 01-6-07 Japan)	“Motorcycle exhaust system”
600/2008	Merck & Co., Inc. USA (Priority 28-11-05 USA) Divisional	“Heterocycle-substituted 3-alkyl azetidines derivatives”
601/2008	1. Abbott Laboratories USA 2. Abbott GmbH & Co. KG,	“Humanized antibodies to A β (20-42) globulomer and uses thereof”

	Germany (Priority 30-5-07 USA)	
602/2008	VeriTainer Corporation, USA	“Radiation detection unit for mounting a radiation sensor to a container crane”
603/2008	VeriTainer Corporation, USA	“Real time system for mounting containers from a quayside crane”
604/2008	Wyeth, USA (Priority 30-5-07 USA)	“Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans”
605/2008	Bayer HealthCare LLC. USA (Priority 30-5-07 USA)	“System and method for managing health data”
606/2008	Bayer HealthCare LLC. USA (Priority 30-5-07 USA)	“Architecture for health monitoring systems”
	<u>30-5-2008</u>	
607/2007	Bayer BioScience N. V., Belgium (Priority 01-6-07 Europe)	“Novel genes encoding insecticidal proteins”
608/2008	SmithKline Beecham Corporation, USA (Priority 01-6-07 USA)	“Imidazopyridine kinase inhibitors”
609/2008	Boehringer Ingelheim International GmbH, Germany (Priority 01-6-07 Europe)	“Dispensing device”
610/2008	Arjowiggins Licensing France (Priority 31-5-07 France)	“A crumple-resistant security sheet, a method of manufacturing such a sheet, and a security document including such a sheet”
	<u>31-5-2008</u>	
611/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 28-9-04 Japan) Divisional	“A slat of a carbostyryl compounds”



APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as curtained on application to the office.

870/1998	Boehringer Ingelheim Pharmaceuticals, Inc. USA.	“Pharmaceutical Suspension Comprising nevirapine Hemihydrate” (A61P 31/18)	139567
----------	---	---	--------

An aqueous pharmaceutical suspension consisting essentially of nevirapine hemihydrate having a particle size between about 1 and 150 microns in diameter”

545/2000	Janssen Pharmaceutica NV. Belgium.	“Benzimidazole” (C07D 401/12 A61K 31/437)	139568
----------	---	--	--------


This invention concerns the compound of formula



prodrugs, N-oxides, addition salts, quaternary amines, metal complexes or stereochemically isomeric forms thereof wherein $-(a)^1=(a)^2-(a)^3=(a)^4$ is a radical of formula

$-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$,

$-\text{CH}=\text{CH}-\text{CH}=\text{N}-$ wherein each hydrogen atom may optionally be substituted; Q is a radical of formula




wherein Alk is C_{1-6} alkanediyl; Y^1 is a bivalent radical of formula $-NR^2-$ or $-CH(NR^2R^4)-$; X^1 is NR^4 , S, $S(=O)$, $S(=O)_2$, O, CH_2 , $C(=O)$, $CH(=CH_2)$, $CH(OH)$, $CH(CH_3)$, $CH(OCH_3)$, $CH(SCH_3)$, $CH(NR^{5a}R^{5b})$, CH_2-NR^4 or NR^4-CH_2 ; X^2 is a direct bond, CH_2 , $C(=O)$, NR^4 , C_{1-4} alkyl- NR^4 , NR^4-C_{1-4} alkyl; t is 2 to 5; u is 1 to 5; v is 2 or 3; and whereby each hydrogen in Alk and in (b-3), (b-4), (b-5), (b-6), (b-7) and (b-8), may optionally be replaced by R^3 ; provided that when R^3 is hydroxy or C_{1-6} alkyloxy, then R^3 can not replace a hydrogen atom in the α position relative to a nitrogen atom; G is substituted C_{1-10} alkanediyl wherein the substituent is attached via an oxygen atom; R^1 is an optionally substituted monocyclic heterocycle or aryl; R^2 is hydrogen, formyl, C_{1-6} alkylcarbonyl, Hetcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, C_{3-7} cycloalkyl or C_{1-10} alkyl substituted with $N(R^6)_2$ and optionally with another substituent; R^3 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, aryl C_{1-6} alkyl or aryl C_{1-6} alkyloxy; R^4 is hydrogen, C_{1-6} alkyl or aryl C_{1-6} alkyl; R^{5a} , R^{5b} , R^{5c} and R^{5d} are hydrogen or C_{1-6} alkyl; or R^{5a} and R^{5b} , or R^{5c} and R^{5d} taken together from a bivalent radical of formula $-(CH_2)_s-$ wherein s is 4 or 5; R^6 is hydrogen, C_{1-4} alkyl, formyl, hydroxy C_{1-6} alkyl, C_{1-6} alkylcarbonyl or C_{1-6} alkyloxycarbonyl; aryl is optionally substituted phenyl; Het is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; as respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and their use as a medicine.


522/2002 F. Hoffmann-La "4'-Substituted Nucleoside"
 Roche AG.
 Switzerland. (C07H 19/06 A61K 31/708)

139569


The present invention relates to 4-Substituted nucleoside compound of formula I



wherein B signifies a 9-purinylyl residue B1 of formula



or a 1-pyrimidyl residue B2 of formula



wherein the symbols are as defined in the specification, for the treatment of diseases mediated by the Hepatitis C Virus (HCV), to pharmaceutical composition containing such compound.


910/2002 Pfizer Products
Inc.
USA.

“3-Azabicyclo[3.1.0] Hexane Compound and
Composition Containing Them”

(INT: CL, C07D 209/52)

139570

The subject invention provides a compound of the
formula I,




Wherein X, Q, n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are as defined. Compound of formula I have activity as opioid receptor antagonist. The subject invention furthermore provide for pharmaceutical composition and therapeutic method comprising compound of formula I.

360/2005 Altana Pharma
AG.
Germany. “Novel Dialkoxy-imidazopyridine”
(C07D 471/04)

139571

The invention relates to novel dialkoxy
Imidazopyridine having a chemical structure according
to formula 1.




With R1 being 1-4C-alkoxy or 3-7C-cycloalkyl-1-4C-alkoxy, R2 being 1-4C-alkoxy, R3 being 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy and R4 being hydrogen or 1-4C-alkyl. The compound overcome the known stability problems of the prior art compound and can be used for acid inhibition in the stomach. The invention further is directed to medicaments comprising these compounds.

449/2005 F. Hoffmann-La
Roche AG.
Switzerland. “4-Hydroxy-4-Methyl-Piperidine-1-Carboxylic acid
(4-methoxy-7-Morpholin-4-yl-benzothiazol-2-yl)-
amide”

(INT: CL, C07D 417/12, 417/14, 417/00)

1339572

The present invention relates to the compound of
formula.



Which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl)-amide, It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics,

antiepileptics, anticonvulsants and cardioprotective agents.

1137/2005 ENI S.P.A. and Enitecnologie S.p.A., Italy.

“A Process for the Dehydration of a Gase by using polyethylene glycol, its Regeneration and Recycling thereof”

(INT: CL, B01D 53/28)

139573

Process for the dehydration of gases, comprising: absorbing water vapour by means of a hygroscopic liquid consisting essentially of one or more C2-C8 glycols and an additive capable of forming a minimum type azeotrope with water; distilling the glycol/ water/ additive mixture to obtain a top product consisting mainly of the water/additive azeotropic mixture and a bottom product consisting mainly of glycol and additive (hygroscopic liquid); recycling the regenerated hygroscopic liquid to the absorption stage.


177/2007 Pfizer Products Inc. USA.

“Mesylate Salt of exo-N-{3-[6-ethyl-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.1.0] hex-6-yl]-phenyl}-methanesulfonamide”


(INT: CL, C07D 209/52)

139574

The subject invention provide mesylate salt of a compound of the formula I,



Wherein X, Q, n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are as defined mesylate salt of Compound of formula I have activity as opioid receptor antagonist. The subject invention furthermore provide for pharmaceutical composition and therapeutic method comprising salt of compound of formula I.



SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139316 GCG Holding Ltd.
Bahamas

365/2005

(Mrs. Yasmeen Abbasi)
Controller of Patents
Tel: 9215488